Sana Biotechnology, Inc.

SANA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
94
SEC Filings

Business Summary

PART I O verview We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologic drugs to clinical practice, enabling us to repair cells in the body when possible and replace them when needed. We have developed ex vi...

Next Earnings

Q2 FY2026 — expected 2026-09-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSANAdiscussed_in_filing Cybersecurity
topic_mentionSANAdiscussed_in_filing Cybersecurity
topic_mentionSANAdiscussed_in_filing Healthcare & Bio
topic_mentionSANAdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-032025-12-310001193125-26-088215EDGAR143K words
2025-03-172024-12-310000950170-25-040254EDGAR—
2024-02-292023-12-310000950170-24-023119EDGAR—
2023-03-162022-12-310001564590-23-003798EDGAR—
2022-03-162021-12-310001564590-22-010539EDGAR—
2021-03-242020-12-310001193125-21-092650EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269569EDGAR91K words
2025-08-112025-06-300001770121-25-000010EDGAR—
2025-05-082025-03-310000950170-25-066943EDGAR—
2024-11-082024-09-300000950170-24-123730EDGAR—
2024-08-082024-06-300000950170-24-094052EDGAR—
2024-05-082024-03-310000950170-24-055727EDGAR—
2023-11-082023-09-300000950170-23-061171EDGAR—
2023-08-032023-06-300000950170-23-038050EDGAR—
2023-05-082023-03-310001564590-23-007074EDGAR—
2022-11-022022-09-300001564590-22-036375EDGAR—
2022-08-042022-06-300001564590-22-028036EDGAR—
2022-05-102022-03-310001564590-22-019299EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-030001193125-26-088203EDGAR5K words
2026-02-170001193125-26-053294EDGAR—
2026-01-140001193125-26-012664EDGAR—
2025-11-060001193125-25-269522EDGAR—
2025-09-050001193125-25-196414EDGAR—
2025-08-290001193125-25-192766EDGAR—
2025-08-110001770121-25-000009EDGAR—
2025-08-070001193125-25-175571EDGAR—
2025-08-060001193125-25-174506EDGAR—
2025-06-230000950170-25-088752EDGAR—

94 total filings indexed. 66 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001770121
TickerSANA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: af62430962bbffae636dad77452359c4c3d3f35ec39c2b16dd20834230bc6c4a
parent: 2e22d7e7b4441c29bc871d759e3f5b864a31825f47f16682c1aad66d5cb1692c
content hash: 10394b439948e3f9610cfd1718e164a72adc0432362ee2b6f527529bfd68f1e2
signed: 2026-04-13T04:47:19.005Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf